EP Patent

EP3615541C0 — POLYMORPHS, SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND PROCESSES FOR THEIR PRODUCTION

Assigned to F Hoffmann La Roche AG · Expires 2025-03-19 · 1y expired

What this patent protects

Patent listed against Itovebi.

Drugs covered by this patent

Patent Metadata

Patent number
EP3615541C0
Jurisdiction
EP
Classification
—
Expires
2025-03-19
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.